Skip to main content

REVIEW article

Front. Cell. Neurosci.
Sec. Cellular Neuropathology
Volume 18 - 2024 | doi: 10.3389/fncel.2024.1485414
This article is part of the Research Topic CNS Disease Cell Models and Targeted Drug Discovery View all articles

The BE (2)-M17 neuroblastoma cell line: revealing its potential as a cellular model for Parkinson's disease

Provisionally accepted
Angel Carvajal-Oliveros Angel Carvajal-Oliveros 1Camila Román Martínez Camila Román Martínez 1Enrique Reynaud Enrique Reynaud 2Eduardo Martínez-Martínez Eduardo Martínez-Martínez 1*
  • 1 National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico
  • 2 Institute of Biotechnology, National Autonomous University of Mexico, Cuernavaca, Morelos, Mexico

The final, formatted version of the article will be published soon.

    Parkinson's Disease is a pathology with a wide range of in vivo and in vitro models available. Among these, the SH-SY5Y neuroblastoma cell line is one of the most employed. This model expresses catecholaminergic markers and can differentiate and acquire various neuronal phenotypes. However, challenges persist, primarily concerning the variability of growth media, expression of dopaminergic markers, and a wide variety of differentiation protocols have been reported in the literature without direct comparison between them. This lack of standardized differentiation conditions impacts result reproducibility and makes it very difficult to compare the results obtained from different research groups. An alternative cellular model is the BE (2)-M17, derived from neuroblastoma, which exhibits a high basal expression of numerous dopaminergic markers such as tyrosine hydroxylase, VMAT2 and DAT. The BE (2)-M17 cells show neuronal properties, grows rapidly in conventional media, and can easily be differentiated to increase their dopaminergic phenotype. In this review, we will thoroughly explore the properties of the BE (2)-M17 cell line and discuss its potential as an excellent model for studying Parkinson's Disease.

    Keywords: BE (2)-M17, SH-SY5Y, Parkinson's disease, Neuroblastoma, Dopamine, tyrosine hydroxylase

    Received: 23 Aug 2024; Accepted: 04 Nov 2024.

    Copyright: © 2024 Carvajal-Oliveros, Román Martínez, Reynaud and Martínez-Martínez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Eduardo Martínez-Martínez, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.